Ph.D. Chemistry, University of Delhi, Delhi, India 1997
Postdoctoral training at Yale University and Emory University
Ritu Aneja, Professor at Georgia State University, specializes in cancer cell biology, cancer selective “druggable” targets, chemotherapeutic modalities and chemoprevention strategies, cancer related health disparities
Ritu earned her Ph.D. in Chemistry, University of Delhi, Delhi, India, and received her Postdoctoral training at Yale University and Emory University.
Centrosomes, Cell Cycle and Cancer
Cancer is a surreptitious killer that has touched our lives in one way or another. It is no wonder that the disease is described as the defining plague of our generation. Fortunately, decades of exhaustive research have yielded a battery of chemotherapeutic agents, the most notable of which include tubulin-binding drugs. Although these drugs can be effective to varying degrees in killing cancer cells, they are notorious for their debilitating toxic side effects.
Our laboratory is devoted to address the urgent unmet clinical need for novel centrosome-based “druggable” targets, and clinical biomarkers for early cancer detection and prediction of metastasis risk. We are also examining cancer related health disparities among African American and European American populations at the cell biological level. The long range goal is to be able to contribute "kinder and gentler” chemotherapeutic modalities to the clinic that have superior pharmacological profiles. In order to meet our goals, we are also exploring Mother Nature’s chest of medicine by evaluating the efficacy of various plant based foods which are an abundant source of cancer chemopreventive dietary phytochemicals for the therapy and management of prostate and breast cancers.
The overarching, long-term goal is to improve patient outcomes by increasing disease-free survival and enhancing patients' quality of life. Explore these pages to discover the pressing research questions we are currently investigating using biochemical, molecular, and cellular biological techniques with human clinical specimens, in vivo preclinical mice models, in vitro continuous cultures, and in silico systems.
1. Ogden A, Rida PC, Reid MD, Aneja R. Interphase microtubules: chief casualties in the war on cancer? Drug Discov Today. 2013 Nov 4.
2. Gundala SR, Yang C, Lakshminarayana N, Asif G, Gupta MV, Shamsi S, Aneja R. Polar biophenolics in sweet potato greens extract synergize to inhibit prostate cancer cell proliferation and in vivo tumor growth. Carcinogenesis. 2013 Sep;34(9):2039-49.
3. Paranjpe R, Gundala SR, Lakshminarayana N, Sagwal A, Asif G, Pandey A, Aneja R. Piper betel leaf extract: Anticancer benefits and bio-guided fractionation to identify active principles for prostate cancer management. Carcinogenesis. 2013 Jul;34(7):1558-66.
4. Brahmbhatt M, Gundala SR, Asif G, Shamsi SA, Aneja R. Ginger phytochemicals exhibit synergy to inhibit prostate cancer cell proliferation. Nutr Cancer. 2013 Feb;65(2):263-72.
5. Ogden A, Rida PC, Aneja R. Heading off with the herd: how cancer cells might maneuver supernumerary centrosomes for directional migration. Cancer Metastasis Rev. 2013 Jun;32(1-2):269-8.
6. Pannu V, Rida PC, Ogden A, Clewley R, Cheng A, Karna P, Lopus M, Mishra RC, Zhou J, Aneja R. Induction of robust de novo centrosome amplification, high-grade spindle multipolarity and metaphase catastrophe: A novel chemotherapeutic approach. Cell Death and Disease 2012; Jul 12;3:e346.
7. Ogden A, Rida PC, Aneja R. Let's huddle to prevent a muddle: Centrosome declustering as an attractive anticancer strategy. Cell Death Differ. 2012; Aug;19(8):1255-67).
8. Karna P, Rida PC, Gao J, Gupta M, Fritz A, Werner E, Yates C, Zhou J, Aneja R. A novel microtubule-modulating agent inhibits angiogenesis by repressing the HIF-1alpha axis and disrupting cell polarity and migration. Carcinogenesis 2012 Sep;33(9):1769-81.
9. Madan J, Baruah B, Mulpuri N, Abdalla MO, Yates C, Turner C, Rangari V, Hamelberg D, Aneja R. Molecular cycloencapsulation augments solubility and improves therapeutic index of brominated noscapine in prostate cancer cells. Mol Pharm 2012 May 7;9(5):1470-80.
10. Karna P, Rida CGP, Pannu V, Gupta KK, Dalton BW, Joshi HC, Yang VW, Zhou J, Aneja R. A novel microtubule-modulating noscapinoid triggers apoptosis by inducing spindle multipolarity via centrosome amplification and declustering Cell Death Differ. 2011;18(4):632-44.
11. Karna P, Gundala SR, Gupta MV, Shamsi SA, Pace RD, Yates C, Narayan S, Aneja R. Polyphenol-rich sweet potato greens extract inhibits proliferation and induces apoptosis in prostate cancer cells in vitro and in vivo. Carcinogenesis. 2011 Dec;32(12):1872-80.
12. Stanton R, Gernert KM, Nettles JH, Aneja R. Drugs that target dynamic microtubules: A new molecular perspective. Med. Res. Rev. 2011;31(3):443-81.
13. Mishra RC, Karna P, Gundala SR, Pannu V, Stanton RA, Gupta KK, Robinson MH, Lopus M, Wilson L, Henary M, Aneja R. Second generation benzofuranone ring substituted noscapine analogs: Synthesis and biological evaluation. Biochem Pharmacol. 2011 Jul 15;82(2):110-21.
14. Pannu V, Karna P, Sajja HK, Shukla D, Aneja R. Synergistic antimicrotubule therapy for prostate cancer. Biochem Pharmacol. 2011 Feb 15;81(4):478-87.
15. Abdalla MO, Karna P, Sajja HK, Mao H, Yates C, Turner T, Aneja R. Enhanced noscapine delivery using uPAR-targeted optical-MR imaging trackable nanoparticles for prostate cancer therapy. J Control Release 2011 Feb 10;149(3):314-22
16. Karna P, Zughaier S, Pannu V, Simmons R, Narayan S, Aneja R. Induction of reactive oxygen species-mediated autophagy by a novel microtubule-modulating agent. J Biol Chem. 2010 Jun 11;285(24):18737-48.
17. Karna P, Sharp S, Yates C, Prakash S, Aneja R. EM011 activates a survivin-dependent apoptotic program in human non-small cell lung cancer cells. Mol Cancer. 2009 Oct 30;8(1):93.
18. Aneja R, Lopus M, Zhou J, Vangapandu SN, Ghaleb A, Yao J, Nettles JH, Zhou B, Panda D, Chandra R, Joshi HC. Rational design of the microtubule-targeting anti-breast cancer drug EM015. Cancer Res. 2006;66:3782- 3791.
19. Aneja R, Zhou J, Vangapandu SN, Zhou B, Chandra R, Joshi HC. Drug-resistant T-lymphoid tumors undergo apoptosis selectively in response to an antimicrotubule agent, EM011. Blood. 2006;107:2486-2492.